2020.01.28
License Agreement Has Been Entered into with ReGen Theranostics, Inc.
License-Out
We have executed a license agreement with ReGen Theranostics, Inc. (Rochester, MN, U.S.A.) for the use of iPS cell-derived cardiomyocytes products for regenerative therapy under the patents on iPS cell related technologies licensed to us by Kyoto University.